Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors?

Canadian Journal of Psychiatry

Volumn 46, Issue 3, 2001, Pages 258-263

  Dalfen, A K ^a   Stewart, D E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adverse drug reactions; Cardiovascular disease; Drug interactions; Intentional overdose; SSRIs

Indexed keywords

ALCOHOL; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; NARCOTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMORBIDITY; DATA BASE; DRUG INTOXICATION; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT MONITORING; PRESCRIPTION; PREVALENCE; RISK FACTOR; SEX DIFFERENCE;

EID: 0035010793     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370104600306     Document Type: Article

References (38)

1. Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialties
2. Serotonin-specific reuptake inhibitors
3. Risks and benefits of selective serotonin reuptake inhibitors in treatment of depression
4. Selective serotonin reuptake inhibitors: Infrequent medical adverse effects
5. Gender differences in treatment response to sertraline versus imipramine in chronic depression
6. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
7. Antidepressant treatment and side effect considerations
8. Genitourinary and sexual adverse effects of psychotropic medication
9. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antide-pressants
10. Unstable angina associated with sertraline
11. Fluoxetine-induced bradycardia and syncope in two patients
12. Bradycardia and syncope induced by fluoxetine
13. Are there special considerations in the prescription of serotonin reuptake inhibitors for women?
14. Cardiac Drug and psychotropic drug interactions: Significance and recommendations
15. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
16. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: Prevalence, distress and causation
17. Antidepressants and suicidal risk
18. Alcohol and drugs in suicides
19. Sudden chest pain with sertraline
20. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina
21. Are psychotropic drugs at therapeutic levels a concern for cardiologists?
22. Cardiovascular effects of fluoxetine in depressed patients with heart disease
23. Electro-cardiographic effects doxepin in patients with major depressive disorder of fluoxetine
24. The medical consequences of the selection of an antidepressant
25. Newer antidepressants and the cytochrome P450 system
26. Mechanism of the cardiotoxic actions of terfenadine
27. Torsades de pointes induced by erythromycin
28. Hemodynamic effects of extracardiac drugs
29. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
30. Effects of gender on cardiac arrhythmias
31. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
32. Sex difference in risk of torsade de pointes with d,l-sotalol
33. Can treating depression reduce mortality after an acute myocardial infarction?
34. Canada Canadian adverse drug reaction newsletter
35. QTc prolongation and increased cardiac risks